Shalini Chhabra, MD
Geriatric Medicine · Morgantown, KYNPI 1629141817
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,529 of the $1,724 with a category attached, or 88.7%. It is spread thinly across 42 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,550, more than ten times the $12 reported in 2020.
Across 63 payments — averaging $27.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$232
- Lilly USA, LLC$126
- AVEO Pharmaceuticals, Inc.$115
- Daiichi Sankyo Inc.$102
- AbbVie$95
- Pharmaessentia USA Corporation$74
- plus $980 from 36 others
What the payments were for
- Food & beverage$1,52989%
- Education$19511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 6 | $232 |
| Lilly USA, LLC | 1 | $126 |
| AVEO Pharmaceuticals, Inc. | 2 | $115 |
| Daiichi Sankyo Inc. | 5 | $102 |
| AbbVie | 1 | $95 |
| Pharmaessentia USA Corporation | 3 | $74 |
| Boehringer Ingelheim | 2 | $66 |
| Pfizer | 3 | $66 |
| Merck | 3 | $62 |
| Johnson & Johnson | 2 | $45 |
| Coherus Oncology, Inc. | 2 | $43 |
| Medtronic | 2 | $41 |
| Legend Biotech USA Inc. | 2 | $39 |
| Geron Corporation | 1 | $35 |
| EMD Serono, Inc. | 1 | $31 |
| Immunocore Limited | 1 | $26 |
| Rigel Pharmaceuticals, Inc. | 1 | $26 |
| Genentech USA, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Taiho Oncology, Inc. | 1 | $25 |
| GSK | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Gilead | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $22 |
| Bayer | 1 | $21 |
| Sanofi | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Sandoz | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Nuvation Bio Inc. | 1 | $14 |
| Stemline Therapeutics Inc. | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,724 in reported general payments places this provider in the 75th percentile of 33 geriatric medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 89 | $67,197 |
| XolairOmalizumab | 12 | $62,150 |
| JanuviaSitagliptin Phosphate | 79 | $60,979 |
| RybelsusSemaglutide | 26 | $48,300 |
| OzempicSemaglutide | 37 | $36,490 |
| BrilintaTicagrelor | 63 | $32,973 |
| MounjaroTirzepatide | 34 | $32,806 |
| XareltoRivaroxaban | 32 | $30,860 |
| JardianceEmpagliflozin | 28 | $28,599 |
| FarxigaDapagliflozin Propanediol | 25 | $23,234 |
| Memantine Hcl ErMemantine Hcl | 81 | $16,018 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $14,956 |
| MyrbetriqMirabegron | 20 | $10,542 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,044 |
| LinzessLinaclotide | 12 | $6,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $12 | $84,78963 claims |
| PfizerEliquis | $66 | $67,19789 claims |
| MerckJanuvia, Janumet | $62 | $64,95790 claims |
| AstraZenecaBrilinta, Farxiga | $17 | $56,20788 claims |
| Lilly USA, LLCMounjaro | $126 | $32,80634 claims |
| Johnson & JohnsonXarelto | $45 | $30,86032 claims |
| Boehringer IngelheimJardiance | $66 | $28,59928 claims |
| GSKTrelegy Ellipta, Arexvy | $25 | $19,90836 claims |
| AbbVieLinzess | $95 | $6,53312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 geriatric medicine providers in Kentucky.
Other geriatric medicine in Morgantown
- Rachel HartLouisville$34K
- Maria AtienzaCorbin$16K
- Josephine GomesLouisville$11K
- Gina D'costaRichmond$4K
- Azizullah MehrzadOwensboro$3K
- Andrew CollinsOwensboro$2K
- Emmanuel YumangLondon$2K
- Svitlana MandzyLouisville$2K
- Joseph MitchellOwensboro$949
- Priyank ChauhanLeitchfield$797
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.